Stockreport

Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? [Yahoo! Finance]

Viking Therapeutics, Inc.  (VKTX) 
Last viking therapeutics, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vikingtherapeutics.com
PDF Viking Therapeutics recently completed patient enrollment in its Phase 3 VANQUISH-1 trial for VK2735, targeting obesity with a dual GLP-1/GIP receptor agonist, while rep [Read more]